KEYTRUDA vs PADCEV

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 18, 2026·How we rate

Possible drug interaction. KEYTRUDA and PADCEV are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	KEYTRUDA	PADCEV
Rating	70/100	72/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	PEMBROLIZUMAB	ENFORTUMAB VEDOTIN-EJFV
Manufacturer	Merck Sharp Dohme	Astellas
Dosage forms	Injectable	Injectable
Drug class	Programmed Death Receptor-1 Blocking Antibody	—
Boxed warning	None	Boxed warning
Treats	Malignant Mesothelioma, Biliary Tract Neoplasms, Urinary Bladder Neoplasms	Urinary Bladder Neoplasms

keytruda padcev

Rating

70/100

72/100

Pharmacy pays

—

Type

Active ingredient

PEMBROLIZUMAB

ENFORTUMAB VEDOTIN-EJFV

Manufacturer

Merck Sharp Dohme

Astellas

Dosage forms

Injectable

Drug class

Programmed Death Receptor-1 Blocking Antibody

—

Boxed warning

None

Boxed warning

Treats

Malignant Mesothelioma, Biliary Tract Neoplasms, Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Frequently asked questions

Which is better-rated, Keytruda or Padcev?

By our independent rating, Padcev scores higher — 3.6 vs 3.5 out of 5 for Keytruda. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Keytruda and Padcev?

Keytruda contains Pembrolizumab, while Padcev contains Enfortumab Vedotin-Ejfv — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.